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Abstract
Background: DNA microarrays are popular tools for measuring gene expression of biological
samples. This ever increasing popularity is ensuring that a large number of microarray studies are
conducted, many of which with data publicly available for mining by other investigators. Under most
circumstances, validation of differential expression of genes is performed on a gene to gene basis.
Thus, it is not possible to generalize validation results to the remaining majority of non-validated
genes or to evaluate the overall quality of these studies.
Results: We present an approach for the global validation of DNA microarray experiments that
will allow researchers to evaluate the general quality of their experiment and to extrapolate
validation results of a subset of genes to the remaining non-validated genes. We illustrate why the
popular strategy of selecting only the most differentially expressed genes for validation generally
fails as a global validation strategy and propose random-stratified sampling as a better gene selection
method. We also illustrate shortcomings of often-used validation indices such as overlap of
significant effects and the correlation coefficient and recommend the concordance correlation
coefficient (CCC) as an alternative.
Conclusion:  We provide recommendations that will enhance validity checks of microarray
experiments while minimizing the need to run a large number of labour-intensive individual
validation assays.
Background
Microarrays provide large-scale comparative gene expres-
sion profiles between biological samples by simultane-
ously detecting either expression or differential expression
in thousands of genes. The lack of agreement among vari-
ous technologies putatively measuring the same processes
has prompted calls for microarray results to be validated
with other technologies before they are published [1,2].
Microarray findings are usually validated on a gene-by-
gene basis to lend support to biological models. It is not
always clear, however, the extent to which the validation
of these genes reflects the entire microarray experiment, in
part because validation procedures often fall short of opti-
mal sampling and statistical requirements [3]. Thus,
microarray results where only a handful of genes have
been validated, with little concern regarding the remain-
der of the data, are common. Moreover, public repositor-
ies of microarray experiments contain an ever increasing
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number of archived studies for which it is not readily pos-
sible to evaluate the quality. Global validation of microar-
ray experiments is necessary to address these
shortcomings. A global validation approach should pro-
vide an index of the quality of the fold-change estimates
regarding all differentially expressed genes. Such an
approach would be a valuable tool for investigators to
assess the value of their microarray experiments. Further-
more, if routinely provided in archived gene expression
experiments, global validation information would iden-
tify studies most useful for hypothesis generation and
would also provide a study confidence index that could be
used for several applications including meta-analysis [4]
and Bayesian network modelling [5]. Three important
aspects of global validation must be considered: what
measurement should be validated, how should a subset of
differentially expressed genes be chosen for follow-up,
and what statistical evidence is needed to confirm valida-
tion of the microarray results in total?
It has been proposed that fold-change (FC), rather than
raw expression, is the appropriate measure for comparing
results across platforms [6,7]. Otherwise, various technol-
ogy-specific artifacts (e.g., probe-specific biases across
microarray platforms, amplification bias in PCR) can
compromise direct comparisons between gene expression
measurements. At the same time, there is general consen-
sus that whereas FC is a reasonable measure of effect size,
it is inadequate as a test-statistic [20].
Investigators may select genes for validation based on rea-
gent availability or they may select genes based on ad-hoc
or a-priori biological models. One common strategy is to
select the largest FCs or the most statistically significant
differentially expressed genes, based on the idea that large
effects are more likely to be valid [8]. Such non-random
sampling strategies have limited utility as gene selection
procedures because validation results do not readily gen-
eralize to the entire set of differentially expressed genes.
Moreover, the "regression toward the mean" statistical
artifact [9,10], whose effects are exacerbated by selecting
genes with the largest FCs, may lead to underestimating
the global level of agreement between microarray and val-
idation samples. We describe two random sampling strat-
egies which provide data appropriate for global
validation.
Finally, what statistical evidence is needed to assess global
validation? Perfect agreement between two sets of FC
measurements is indicated by correspondence of the
paired data points to the identity line (regression slope of
1 with a y-intercept of 0). Extent of agreement between
this identity line and the data is not captured, however, by
the commonly-used Pearson r correlation coefficient. For
example, high r2 values could be obtained between two
sets of observations even if the average of one set differed
greatly from the other (good precision in predicting one
set based on the other, but poor accuracy). By contrast,
low r2 values could be obtained, despite the two sets agree-
ing quite well on average (good accuracy in predicting one
set based on the other, but poor precision). A better indi-
cator of validation is provided by the concordance corre-
lation coefficient (CCC) [11-13], which combines
accuracy and precision coefficients in one index.
The CCC can vary from 1 (perfect agreement) to -1 (per-
fect reversed agreement), with zero representing no agree-
ment. Its precision coefficient squared is the Pearson r2,
which measures how close the data points are to the least-
squares regression line; the CCC's accuracy coefficient
measures how closely the regression line agrees with the
identity line. Precision-squared and accuracy can vary
from zero (no agreement) to 1 (perfect agreement). CCC
values can be small because precision is low, accuracy is
low, or both.
We present simulated and empirical (microarray and
qrPCR) data to illustrate deficiencies in selecting only the
largest effects for retest and to propose better gene selec-
tion methods. We also examine frequently-used statistical
metrics for assessing validation and contrast their per-
formance with the CCC index. We show that CCC is a use-
ful predictor of global validation of microarray
experiments, and that it can be used as an index of quality
for all microarray studies.
Results
Performance of sampling strategies using simulated data
The selection of a subset of genes for global validation is
critical. To evaluate the effects of sampling, we compared
three strategies (random-stratified, random, and top-
ranked sampling) by generating 1000 simulated data sets
each containing 100 upregulated genes. These 100 FCs
were simulated to correlate approximately 0.80 with retest
FCs; for each simulation run, 10 observations were
selected for each sampling strategy (see Methods). The
output from one of the simulation runs is presented in
Figure 1A. For each simulation run, five measures were
calculated for the full (benchmark) set of 100 observa-
tions and for each of the three sampling strategies: least-
squares regression slopes and y-intercepts, CCCs (and the
constituent accuracy and precision coefficients).
Boxplots of the statistical indices produced by the 100
benchmark values and by the 10 values for each of the
three sampling strategies across the simulation runs are
shown in Figures 1C–G (see also Additional file 1). Fig-
ures 2A–E display the 100 benchmark values subtracted
from the calculated values for each sampling strategy,
reflecting how closely the respective strategies approxi-BMC Bioinformatics 2006, 7:333 http://www.biomedcentral.com/1471-2105/7/333
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mate the ideal of validating all genes [see Additional file
1].
The top-ranked sampling procedure produced inferior
estimates of all five statistical indices relative to random
and random-stratified sampling. Slope and y-intercept
values were accurately estimated across all sampling
methods, although estimates for top-ranked sampling
were highly variable (Figures 1C and 1D, 2A and 2B).
Moreover, 6.8% of the slopes for the top-ranked samples
were negative (i.e., in the opposite direction) compared to
Simulation of fold-change (FC) validation Figure 1
Simulation of fold-change (FC) validation. A scatter plot from one simulation iteration is shown in (A) where the 
selected genes are circled in orange (random-stratified), green (random) and blue (top-ranked). The regression lines are 
orange (random-stratified), green (random), blue (top-ranked), red (identity) and brown (full benchmark sample). (B) Pair-link 
plot which connects paired data points from (A); the tendency for the lines to cross illustrates regression toward the mean. 
Box plots of the benchmark and the various sampling methods for the 1000 simulations are shown for (C) slope, (D) y-inter-
cept, (E) precision (Pearson r), (F) accuracy and (G) concordance correlation coefficient (CCC). The lines of the box plots are 
color matched as above.
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0.02% (random-stratified) and 0.03% (random) (Figure
1C).
Top-ranked sampling also generated both highly inaccu-
rate (downwardly biased) and highly variable estimates of
precision, accuracy, and CCC compared to random-strati-
fied and random sampling (Figures 1E,F, and 1G, 2C,D,
and 2E, and Additional file 1). Moreover, only 32% of the
top-ranked precision values were greater than 0.63 (the
nominal p < 0.05, two-tailed significance level) compared
to 93% and 87% for the random-stratified and random
samples, respectively (uncorrected for multiple testing
and assuming random sampling) (Figure 2C).
The extent of the bias in the precision estimates of both
random and random-stratified sampling will vary with
the true population correlation and with sample size. This
bias should be, however, negligible in microarray valida-
tion studies. For random sampling, there are formulas
which provide approximate corrections for the negative
bias, which can be as high as 0.03 – 0.04 [14]. To estimate
the size of the bias for the type of stratification in the
present study, we conducted additional simulations
(10,000 runs at a time) in which we varied the number of
"genes" selected per stratum (1–9 of 10). For randomly
stratified data, the upward bias (mean difference with the
benchmark data) of the sample correlation coefficient
ranged from a high of 0.0040 (n = 1 per stratum) to a low
of 0.0003 (n = 9 per stratum).
In summary, random and random-stratified sampling
performed similarly well, although random sampling was
slightly more variable and produced more outliers on all
indices (Figures 1C–G and Additional file 1). Moreover,
the top-ranked sampling strategy performed substantially
worse than either of the two other strategies.
Performance of sampling strategies using empirical 
microarray data
We performed three identical replicate experiments with
mouse NIH 3T3-L1 preadipocytes treated or not with the
steroid hormone dexamethasone (DEX) for 3 h prior to
harvesting. Labelled RNA from each experiment was
hybridized to Affymetrix MG U74Av2 microarrays (see
Simulation of fold-change (FC) validation (difference boxplots) Figure 2
Simulation of fold-change (FC) validation (difference boxplots). Box plots of differences (sampling method minus full 
benchmark sample) for the 1000 simulations are shown for (A) slope, (B) y-intercept, (C) precision (Pearson r), (D) accuracy 
and (E) concordance correlation coefficient (CCC). In each boxplot graph, the dotted line at 0 represents perfect agreement. 
The lines of the box plots represent: orange (random-stratified), green (random) and blue (top-ranked).
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Methods and the MIAME document online). The overlap
of statistically significantly differentially expressed genes
among the three experiments is displayed in a Venn dia-
gram (Figure 3A). A substantial number of genes were sta-
tistically significant in opposite directions across the
experiments, despite setting the false discovery rate (FDR)
at 0.05 within each experiment. Moreover, many more
genes were significant in Experiment 1 because variability
among replicates was substantially lower than in the other
two experiments [see Additional file 2]. One-hundred and
fifty genes were significantly upregulated in all three
experiments (see Methods). Good agreement was
observed among the three microarray replicate experi-
ments for these genes (Figures 3B–D).
To further examine differences in random-stratified versus
top-ranked sampling, we selected 29 of the 150 upregu-
lated genes to validate with qrPCR: the top 15 differen-
tially expressed genes and 14 genes from a random
stratification scheme (Table 1; also see Methods and Addi-
tional file 8). The 15 top-ranked genes and nine of the 14
genes selected by random stratification were significantly
differentially expressed by qrPCR in all three experiments.
Of the remaining five genes in the stratified sample, three
were significant in two experiments (p < 0.005) and two
were significant in one experiment (p < 0.05; see Table 1
and Additional files 1 and 8).
Figure 4 presents validation results from the three micro-
array experiments with aliquots of the same RNA samples
(the type of technical validation that is typically reported).
As with the simulation findings, scatter plots of each
experiment show that gene selection by stratification
yields more accurate and less variable precision and accu-
Concordance between microarray experiments Figure 3
Concordance between microarray experiments. Overlap of statistically significant differentially expressed genes across 
the three repeated microarray experiments is shown in (A). Log2 fold-changes (FCs) for genes which were significantly upregu-
lated in each of the three experiments were averaged across replicates within each experiment (n = 5 for Experiments 1 and 2; 
n = 4 for Experiment 3). Pairwise scatter plots among these averaged FCs are shown in (B-D). The regression lines are: the 
identity line (red), least-squares (blue) and loess (yellow).
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Table 1: List of genes upregulated in the microarray experiments selected for validation by qrPCR
Category Affymetrix RefSeq Title FC Microarray* FC PCR*
Probe Set ID Experiment Average Experiment Average
123 1 2 3
Top 15
1 104598_at dual specificity phosphatase 1 3.96 4.52 5.37 4.58 6.93 6.74 8.36 7.31
2 98817_at follistatin 3.20 4.43 3.83 3.79 4.88 4.92 3.65 4.44
3 93624_at RIKEN cDNA 8430417G17 3.49 3.22 4.30 3.64 9.74 10.50 7.16 9.01
4 93319_at RAS p21 protein activator 3 2.74 5.11 3.13 3.52 4.88 3.34 2.15 3.27
5 160894_at CCAAT/enhancer binding protein delta 3.29 2.95 3.96 3.37 4.49 6.98 7.42 6.15
6 97844_at regulator of G-protein signaling 2 2.79 3.83 3.00 3.17 3.65 3.21 2.70 3.16
7 160564_at lipocalin 2 3.42 2.85 3.27 3.17 8.23 9.81 7.30 8.39
8 96346_at cysteine dioxygenase 1, cytosolic 2.88 3.15 3.34 3.11 2.52 3.41 2.31 2.71
9 160359_at RIKEN cDNA 1190002H23 3.06 2.65 3.18 2.95 6.20 6.14 4.23 5.44
10 92276_at mitogen-activated protein kinase kinase kinase 6 2.75 2.89 3.14 2.92 4.27 4.95 5.42 4.86
11 101030_at ras homolog gene family, member AB 2.81 2.38 3.77 2.93 4.93 5.82 5.56 5.42
12 102867_at TEA domain family member 4 2.85 2.70 3.00 2.85 4.38 5.11 4.43 4.63
13 102896_at downstream of tyrosine kinase 1 2.94 2.27 3.39 2.83 2.55 2.06 2.60 2.39
14 93573_at metallothionein 1 2.83 2.42 2.94 2.72 3.09 3.14 3.36 3.19
15 97950_at xanthine dehydrogenase 2.11 3.89 2.24 2.64 4.64 4.82 2.49 3.82
Stratified
1 160894_at CCAAT/enhancer binding protein delta 3.29 2.95 3.96 3.37 4.49 6.98 7.42 6.15
2 102955_at nuclear factor, interleukin 3 regulated 2.59 2.43 3.06 2.68 4.02 3.42 3.12 3.50
3 92777_at cysteine rich protein 61 2.44 2.20 2.65 2.42 2.74 1.77 2.55 2.31
4 99027_at Bcl2-like 2.21 1.56 2.49 2.05 2.62 1.85 2.19 2.20
5 103644_at dipeptidase 1 (renal) 1.89 2.04 1.87 1.93 5.09 4.49 2.63 3.92
6 100952_at stromal interaction molecule 1 1.81 1.57 1.99 1.78 2.00 1.87 1.26 1.68
7 102984_g_at MAD homolog 1 1.56 1.68 2.07 1.75 1.23 0.95 1.15 1.11
8 161228_f_at enabled homolog 1.69 1.61 1.57 1.62 1.68 1.43 1.42 1.51
9 103432_at interferon-stimulated protein 1.63 1.31 1.65 1.52 1.59 1.40 1.40 1.46
10 96106_at RIKEN cDNA 2400006P09 1.41 1.28 1.79 1.48 1.56 1.50 1.21 1.42
11 100019_at chondroitin sulfate proteoglycan 2 1.32 1.65 1.37 1.44 1.61 1.58 1.04 1.38
12 160924_at cDNA sequence BC028953 1.31 1.40 1.39 1.36 1.62 2.03 1.13 1.55
13 96183_at forkhead box P1 1.34 1.28 1.31 1.31 2.06 1.68 1.52 1.74
14 103890_at expressed sequence AW538196 1.15 1.30 1.29 1.24 1.72 0.82 2.00 1.41
15 104268_at interleukin 6 receptor, alpha 1.18 1.20 1.19 1.19 2.75 2.08 1.48 2.04
* FC is the anti-log of the average log2 FC across the three experiments; for the microarray data, a weighted (by sample size) average was calculated 
(n = 5 for Experiments 1 and 2 and n = 4 for Experiment 3). All microarray FCs were significant (FDR q = 0.05); all non-bolded PCR Fcs were 
significant (nominal p < .05).BMC Bioinformatics 2006, 7:333 http://www.biomedcentral.com/1471-2105/7/333
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Validation of microarray experiments by qrPCR Figure 4
Validation of microarray experiments by qrPCR. Concordance between microarray and qrPCR FCs (averaged across 
within-experiment replicates) for top-ranked (n = 15) and random-stratified sampling methods (n = 15) for each microarray 
experiment is shown in the six scatter plots on the right (B, D, F, H, J, L); corresponding MvA plots are shown on the left (A, 
C, E, G, I, K). The log2 fold-change (FC) values for qrPCR were determined from the calibration curve performed for each 
selected gene. Deleting the red data points in panels B, J, and L, which had large influence on the regression slope (standardized 
slope dfBeta values > 1) had little effect on the CCC values (data not shown). Results of a robust regression approach for 
detecting curvature in H, J, and L yielded inconsistent results; p > 0.10 (H and J) and p < 0.10 (L) (see Methods); least squares 
regression tests for quadratic effects were likewise inconsistent; p values for the quadratic term for H, J, and L were 0.28, 0.08, 
and 0.004, respectively. The regression lines are: the identity line (red), least-squares (blue) and loess (yellow). Random-strati-
fied sampling consistently yields better results than top-ranked sampling.
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Validation of microarray experiments by qrPCR (data averaged across experiments) Figure 5
Validation of microarray experiments by qrPCR (data averaged across experiments). Data in (A) were averaged 
across Figures 4B, D, and F; data in (B) were averaged across Figures 4H, J, and L. (C) Same as in (B) with log2 FCs < 0.5 (red 
+'s) removed. The regression lines are: the identity line (red), least-squares (blue) and loess (yellow).
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racy coefficients compared to top-ranked sampling, with
correspondingly higher CCC estimates. As a point of com-
parison to the CCC index, we also report intraclass corre-
lation [15,16] values.
To obtain more stable estimates of the various indices, we
averaged the data across the three experiments (Figures
5A–B). Compared to sampling top-ranked genes, ran-
dom-stratified sampling was 3.14 times more precise
(0.782 vs. 0.442) and 2.36 times more accurate (0.85 vs.
0.36). Moreover, the CCC was robust to departures from
linearity (Figure 5C), influential regression data points
(Figures 4B,J, and 4L) and log2 FCs < 0.5 [see Additional
file 6].
Results from each microarray experiment were also com-
pared to the qrPCR results obtained from the RNA sam-
ples from the two other experiments (biological
validation), yielding similar results [Additional files 3 and
4]. Figure 6 shows the distributions of the various indices
for the technical and biological validations. Contrary to
expectation, there are no obvious differences between the
technical and biological validation results.
Relation between microarray and qrPCR
Predicted qrPCR FCs were larger than microarray FCs, an
effect which increased with increasing FCs, as indicated by
the least-squares regression (blue) lines being above the
identity (red) lines for most of the data range in Figures 4,
5. This pattern is also evident in Figures 7A–B, which com-
Dot plots of the values for the various validation indices for technical and biological validation samples Figure 6
Dot plots of the values for the various validation indices for technical and biological validation samples. Dot 
plots of (A) slope, (B) y-intercept, (C) precision (Pearson r), (D) accuracy (E) concordance correlation coefficient (CCC) and 
(F) intraclass correlation coefficient (ICC). In each dot plot, the dots represent the comparisons between technical (open dots) 
and biological replicates (filled dots) of microarray to qrPCR experiments. As with the simulated data, the slope and y-inter-
cept results for the top-ranked comparisons are unbiased relative to random-stratified comparisons, but they are more varia-
ble. The precision, accuracy, CCC and ICC estimates are, similar to the simulated data, more variable and downwardly biased.
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bine the data from Figures 5A–B. We note also that we
obtained better validation results (especially with the pre-
cision index) with qrPCR for both sampling strategies
when qrPCR data were calibrated by the standard curve
method rather than assuming 2-fold amplification of the
PCR reaction using the CT measurements (compare Fig-
ures 4 and 5 with Additional files 5 and 7, respectively).
Also, the robust multichip analysis (RMA, [17]) used in
our analysis is one of many algorithms available for nor-
malizing Affymetrix data. Comparison of results with
other normalization algorithms is beyond the scope of the
study and is complicated by the fact that genes were
selected for subsequent validation based on the RMA data.
Caveats notwithstanding, we provide validation indices
for other popular normalization algorithms [dChip (with
and without mismatches) [18], GC-RMA [19], MAS 5.0
[20], and PLIER [21]. The MAS 5.0 FC estimates produced
the highest concordance with the qrPCR FC estimates,
with CCC, precision and accuracy values of 0.77, 0.85 and
0.91 for random-stratified sampling and 0.69, 0.73 and
Validation of microarray experiments by qrPCR (data averaged across experiments; top-ranked and random-stratified data  combined) Figure 7
Validation of microarray experiments by qrPCR (data averaged across experiments; top-ranked and random-
stratified data combined). Data in (A) were combined from Figures 5A and B; (B) Same as in (A) with log2 FCs < 0.5 (yellow 
+'s) removed. (C-D) Standardized (z-scores) data from A-B. (E) Pair-link diagram of data from panel A; apparent regression 
away from the mean is evident by the mostly positive line slopes, especially among the larger microarray FCs. (F) Pair-link dia-
gram of data from panel C; regression toward the mean is evident by the tendency of the lines to cross. Blue data points in all 
graphs are from the top-ranked sampling method; orange points are from the random-stratified method; the single red point 
was included in both samples. The regression lines are: the identity line (red), least-squares (blue) and loess (yellow).
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0.95 for top-ranked sampling, respectively [Additional file
1].
Regression toward the mean
The lower precision and accuracy of the top sampling
strategy can be explained by the regression toward the
mean phenomenon. The phenomenon describes the ten-
dency for extreme values of one set of observations to be
less extreme on a second set. The lower the true correla-
tion and the more extreme the values on the initial set, the
more pronounced the tendency. Note also that regression
toward the mean is bidirectional; the artifact remains if
the initial and the retest sets are reversed.
The regression toward the mean effect depends solely on
the correlation between two sets of observations; it occurs
whenever the correlation is less than perfect (i.e., r2 < 1)
[9,10]. This correlation in turn depends on the variability
of the true (unknown) values and the variability of the
random error associated with the measurements. Reduc-
ing random error (e.g., by stringent quality control proce-
dures) and sampling across the entire data range
maximizes the observed correlation and minimizes the
adverse effects of regression toward the mean. Finally,
although for ease of exposition we conducted our simula-
tions assuming linearity and normally distributed ran-
dom error, the regression toward the mean phenomenon
does not depend on these assumptions [9,10].
The strength of the adverse effect of top-ranked sampling
will depend on the distributions of the microarray and
validated sample data. Accordingly, choice of microarray
and qrPCR preprocessing methods (e.g., background cor-
rection, normalization, transformation, calibration) will
affect the regression toward the mean effect to the extent
that they affect the data distributions, although the effect
will always be present to some degree. Assuming linearity
and homoscedasticity, restricting the microarray data to
the top-ranked effects will underestimate the population
correlation between microarray (x) and validation sam-
ples (y) according to the following formula [22]:
Where ρ and σ are the population correlations and stand-
ard deviations, respectively.
Regression toward the mean can be most easily illustrated
when the two sample means and standard deviations are
at least approximately equal, as is the case for the simu-
lated data in Figure 1 and the microarray-microarray data
in Figure 3. Note the larger distances between the identity
(red) line in Figure 1A and the benchmark data least
squares regression (black) line for the extreme (low and
high) values of the initial sample (x-axis). Similar differ-
ences are seen between the identity (red) line and the least
squares regression (blue) line in Figures 3B–D. For low
initial sample values, predicted values on retest are larger;
for large initial sample values, predicted values on retest
are smaller.
Pair-link diagrams provide another graphical illustration
[9] (Figure 1B). The lines linking the initial scores to their
respective retest scores tend to cross. On average, high
scores on the initial sample have negative (decreasing)
slopes, low scores have positive (increasing) slopes, and
middle scores have flat slopes. The upshot of this ten-
dency is that retest values will have lower precision and
lower accuracy when top-ranked initial values are selected
for retest.
By contrast, the pair-link diagram for the microarray/
qrPCR data (Figure 7E) shows that most lines linking the
microarray FCs to their respective qrPCR FCs have a posi-
tive slope, especially among the top-ranked microarray
values. Despite appearances, regression toward the mean
is nonetheless present and provides an explanation for the
lower level of agreement observed among the top-ranked
genes. This type of apparent "regression away from the
mean" can only occur when the standard deviation of the
validation sample is larger than the standard deviation of
the initial sample, as here (sdqrPCR = 0.85; sdMicroarray =
0.56). Regression toward the mean, however, is a phe-
nomenon of standardized scores (it is simply not neces-
sary for illustration purposes to use standardized scores
when standard deviations are equal). When variance is
taken into account and measurements are converted to
standardized z-scores, the regression toward the mean
effect is evident (Figures 7C, D and F). Extreme standard-
ized qrPCR FCs are less extreme than their corresponding
microarray FCs. Larger sample sizes would be needed to
determine if the lower agreement among the top-ranked
genes is due solely to regression toward the mean or to
regression toward the mean plus some other effect (e.g.,
non-linearity).
Discussion
Routine global validation of microarray results would
provide valuable information on the quality of microarray
studies and would complement existing standards for val-
idating individual genes. Our results demonstrate that the
outcome of global validation depends on how a subset of
genes is chosen. Random-stratified sampling provides
more accurate and more precise estimates of agreement
between microarrays and qrPCR than does the often-used
top-ranked sampling procedure. Our empirical results
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confirm the theoretical argument that selecting top-
ranked differentially expressed genes for validation leads
to underestimating the level of agreement between micro-
array and qrPCR validation FC values.
Genes which are deemed especially important to the
experimenter can be validated separately from genes
required for validation of the microarray experiment in
total. Appreciation for the regression toward the mean
effect, however, is still necessary for informed decisions
regarding these specific genes. The tendency for extreme
FCs to be less extreme on validation will still be operating,
although the non-random sampling will make it difficult
to assess the extent of the effect.
CCC index of validation
We argue that a one-to-one correspondence between
microarray and validation FC estimates is the gold stand-
ard for validation. This tight clustering of retest FC values
around the identity line is indexed uniquely among vali-
dation indices by the CCC measure. Accordingly, the CCC
provides dimensionless metrics with which to compare
technology platforms, statistical procedures, and labora-
tory protocols, and ultimately, the overall quality of any
given microarray study. In the case of unusually low CCC
values, the accuracy and precision components provide
clues on how the validation samples deviate from the
standard which may in turn suggest procedural or statisti-
cal remedies. Regression slope and intercept estimates
provide additional information to convert microarray FC
estimates into estimates from lower throughput methods.
Finally, the reported robustness of the CCC with as few as
10 data points [11] is supported in our data, as influential
(outlier) data points and deviations from linearity had lit-
tle effect on the CCC estimates, although robust ana-
logues of the CCC are also available [23].
Sampling
The relatively high CCC values we observed in pairwise
comparisons between our microarray experiments (Fig-
ures 3B–D) lend support to FC as a good index of effect
size for platform comparison purposes. However, FC
measurements present a statistical technical difficulty
when attempting to validate the entire FC range, including
non-differentially expressed genes. Most log FCs near zero
represent non-differentially expressed genes whose varia-
tion merely reflects noise. Correlation with qrPCR for
these genes will be close to zero and the least squares line
will be flat within this range. Differentially expressed
genes, on the other hand, will have positive slopes for
both up and down regulated genes. If only differentially
expressed genes are selected for validation, up and down-
regulated genes should be examined separately. Analyzing
them together will upwardly bias correlation values due to
a "range enhancement" artifact [22]; in extreme cases, the
correlation between microarray and qrPCR FCs may be
close to 1, despite zero correlations when up and down-
regulated genes are analyzed separately.
The adverse effects of regression toward the mean are
sometimes avoided when specific genes of interest are
selected and they cover the full FC range coincidentally.
The strategy remains less than optimal as a global valida-
tion strategy, however, because the non-random sampling
nonetheless prevents the generalization of the conclu-
sions to the remaining majority of differentially expressed
genes.
Threshold index of validation
All top-ranked, but only nine out of the 14 random-strat-
ified genes in our study were statistically significant by
qrPCR in the three samples. Non-significant p  values
tended to occur among the smaller FCs, but this effect was
not uniform, as the smallest average microarray FC gene
was significant in all three PCR samples. The seemingly
paradoxical difference between the statistical significance
threshold and the CCC approaches to validation can be
explained as follows.
One difficulty with this type of threshold-based strategy is
the choice of threshold. It can be shown that the smaller
the initial p value, the more probable a second test will
meet a specified probability threshold [24,25]. A true pos-
itive gene that is differentially expressed at p = 0.05 has
only a 50% chance of being differentially expressed at p <
0.05 on retest; at p = 0.005, the probability of obtaining p
< 0.05 on retest increases to 80% [24]. Accordingly, the
larger its initial FC, the more likely the gene will exceed
the decision threshold in the validation sample despite
regression toward the mean. This threshold approach to
validation, however, is adequate only if one is interested
in the largest FC effects to the exclusion of more moderate
but potentially important effects.
Additionally, consider the following example. Using a p <
0.05 threshold, a gene that is differentially expressed at p
= 0.049 by microarray but at p = 0.051 by qrPCR would be
said to not have validated despite almost identical p val-
ues. By contrast, a gene that is differentially expressed at p
= 0.0001 by microarray and at p = 0.049 by qrPCR would
be said to have validated despite a large discrepancy in p
values. One way around this difficulty would be to require
that the effect size of the validated sample not be signifi-
cantly different from the effect size of the initial sample
for a conclusion that the gene was validated, although this
raises the additional question of how many replicate sam-
ples would be needed to provide sufficient statistical
power for detecting differences [26]. Moreover, the issue
arises whether a gene would be considered validated if it
were significant in both initial and validated samples butBMC Bioinformatics 2006, 7:333 http://www.biomedcentral.com/1471-2105/7/333
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with significantly different effect sizes in the two samples.
Despite their limitations however, threshold approaches
do provide a framework for dichotomous decisions
regarding whether or not an individual gene has been val-
idated.
The question arises of how one can reach this type of deci-
sion on individual genes with the validation approach
that we are advocating. One approach might be to first
determine the extent of validation across a number of
appropriately (e.g., random, random stratified) sampled
genes by some index of global validation (e.g., CCC). If
the results of global validation were found to be inade-
quate, then the microarray experiment might well be con-
sidered a failure and the validation of individual genes
moot. If on the other hand global validation were found
to be adequate, then regression diagnostic methods might
be used to identify outlier genes whose validation results
deviated from the pattern of the majority of genes for a
variety of reasons (e.g., splice variants; cross-hybridiza-
tion).
These regression outlier genes could then be investigated
further to determine their status; non-outlier genes would
be considered validated.
A corollary to this approach is that one could extend the
conclusion of validity to those microarray findings not
selected for validation with PCR but whose effects fall
within the sampled (and validated) range. Our approach
advocates selection of genes through a random process;
therefore, any index of global validation should be unin-
fluenced by the specific sample selected and should gen-
eralize to the non-validated genes. Moreover, the relative
proportions of outlier and non-outlier genes would pro-
vide an indication of the relative risk involved in making
such a generalization.
Conclusion
Our results point to the importance of gene selection strat-
egy, choice of qrPCR calibration methods, and choice of
validation index in the assessment of microarray valida-
tion results. Sample sizes of 10 to 25 genes should be ade-
quate for most validation purposes, although more
observations may be needed to reliably estimate non-lin-
earity between microarray and validation FC values. The
CCC provides a global indication of the reproducibility of
gene expression FCs estimated by microarrays, providing
that a suitably random procedure is used to select genes
for validation. Thus, we propose that the CCC be used as
a universal measure of study quality.
Methods
Simulated data
FC values were simulated according to the following
model: FC = µ + ε, where µ ~ N (1, 0.2) and ε ~ N (0, 0.1).
That is, for each of the 100 simulated genes, a "true" FC
was randomly generated from a N (1, 0.2) distribution.
Random error for each of these true values was randomly
generated twice from a N (0, 0.1) distribution. Each of the
pair of random error values was added to a single true
value to produce an "initial sample" and a "retest sample"
value. The 0.2 standard deviation across the true FC values
and the 0.1 standard deviation value for ε were selected to
produce an expected correlation of 0.80. The expected cor-
relation between two measurements with iid error associ-
ated with the same true value (here FC) is the ratio of the
variance of the true scores to the variance of the measured
scores as follows (see [16] pp. 134–140):
where  ,  , and   are the variances of the true
scores, the measured scores, and random error, respec-
tively.
For the current simulated data,
Sampling methods
Sampling from simulated or from microarray data was
performed in three different manners. For top-ranked
sampling, 10 (simulated data) or 15 (microarray data)
largest up-regulated FCs were selected. For random sam-
pling, 10 (or 15) observations were randomly selected
from the entire range of upregulated genes. For random-
stratified sampling, the entire list of upregulated genes
was rank ordered according to FCs; the data were then
divided into 10 (or 15) equal-sized bins and one gene per
bin was selected randomly.
Validation indices
The slope and y-intercept indices were estimated by least
squares linear regression [27]. The formula for the CCC
[11-13] is
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where r is the Pearson correlation coefficient,   and 
and   and   are the y  and  x  sample variances and
means, respectively.
Note that rc = r when   =   and  sy = sx .
The CCC can also be written as the product of the accuracy
and the precision coefficients. The precision coefficient is
given by:
Where z are standardized scores (mean of zero with unit
variance).
The accuracy coefficient is given by:
The original SAS code for the CCC index is available from
[28]. We have adapted the code for S-Plus and R, which is
available from the corresponding author.
Robust statistical test for non-linearity
The relation between microarray and qrPCR FCs was
assessed for curvature (Figure 4) by applying the Cramér-
von Mises test to residuals generated by the Theil-Sen
algorithm [29,30]; see [31] for a description of the proce-
dure and S-Plus functions [see Additional file 1 for more
information].
Empirical study design overview
The biological samples used in the microarray study and
the subsequent validation by qrPCR were obtained from
three replicate studies. First, the cell culture experiment
was performed three distinct times, and every time, the 2
samples (1 control and 1 treatment) were divided into
several smaller aliquots. For the microarray hybridization,
total RNA was extracted from these smaller aliquots: (1
control + 1 treatment) × 3 experiments = 6 samples. From
these total RNA samples, five aliquots of total RNA were
labelled and hybridized onto Affymetrix GeneChips;
hence 6 samples × 5 aliquots = 30 Genechips. For qrPCR,
total RNA was extracted from a second set of the smaller
aliquots. For each gene tested, we performed 6 technical
replicates of the qrPCR on each of the 6 samples.
Cell culture, treatment, and RNA extraction
Mouse 3T3-L1 cells, obtained from ATCC, were grown in
DMEM (Invitrogen Canada Inc.) containing 10% char-
coal/dextran treated fetal bovine serum (Hyclone), 2 µM
L-glutamine (Invitrogen) and 100 U/mL penicillin/strep-
tomycin (Invitrogen). Two parallel cultures containing
cells seeded at a density of 6 × 105 per 150-mm plate were
grown for 72 h (to confluence). The culture media was
replaced and the cells were incubated for an additional 48
h. The cells were then treated with 1 µM dexamethasone
(Sigma; dissolved in ethanol) or ethanol (control), for 3 h
and were harvested by adding 6 mL Trizol reagent (Invit-
rogen) directly to each culture dish. The experiment was
repeated three times using successive cell passages. Total
cellular RNA was prepared according to the manufac-
turer's instructions. The samples were quantified by spec-
trophotometry and the RNA integrity was assessed using
Agilent BioAnalyser RNA LabChips.
Microarray probe preparation and hybridization
Biotinylated cRNA probes were prepared for microarray
analysis according to the manufacturer's instructions,
using 10 µg of total RNA. Five aliquots of each sample
were used for probe preparation, and the probes were
hybridized overnight to Affymetrix MG-U74Av2 Gene-
Chips (30 in total). Following hybridization, non-specifi-
cally bound probe was removed by washing using the
GeneChip Fluidics Station 400 (Affymetrix). Specifically
bound probe was detected by incubating the arrays with
streptavidin phycoerthryin (Molecular Probes) and bioti-
nylated anti-streptavidin antibody (Vector Laboratories)
and scanning the chips using a Gene Array Scanner (Agi-
lent). To minimize technical variability, RNA processing
steps (RNA extraction, probe labeling and microarray
hybridization) were performed in parallel for all samples.
Microarray data processing
Data for the three experiments were analyzed on a per
experiment basis. For each experiment, data were normal-
ized by the robust multi-array average (RMA) algorithm
[32]. Differential expression was tested by independent t-
tests and corrected for multiple testing using the false dis-
covery rate procedure [FDR, [33]]. Two-hundred forty-two
genes were significantly differentially expressed in the
same direction in all three experiments (FDR q = 0.05).
Modified t-tests using the significance analysis of microar-
rays procedure [SAM, [34]] were also computed, with del-
tas of 0.25, 0.425, and 0.54269 for experiments 1, 2 and
3, respectively. These deltas corresponded to a false posi-
tive rate of approximately 0.05 and yielded 400 genes
which were significantly differentially expressed in the
same direction in all three experiments (see also the
MIAME document [Additional file 9]). The intersection of
these two lists contained 241 of the 242 genes identified
by t-test alone. Because of the large overlap of the two
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methods, we selected the list generated by t-test as our
final gene list.
These stringent criteria were adopted for two reasons. We
wished to strictly minimize the false positive rate so as to
reflect as accurately as possible the simulation data while
at the same time not using a criterion that was redundant
with the validation indices under examination. It is prob-
able that this approach overlooked a number of differen-
tially expressed genes. As such, although it served the
methodological purposes of the present study, we do not
recommend it as a general analytical strategy inasmuch as
the false negative rate was likely unfavorably high.
Selection of differentially expressed genes for validation
The within-experiment log2 FC averages for the 242 con-
sistently statistically significant genes were calculated and
then averaged across experiments. Downregulated and
four upregulated outlier genes (> 5 MADs) which would
have adversely affected statistical analysis were eliminated
from the list. Twenty-nine genes from the remaining 150
upregulated genes were selected for validation: the top 15
FCs and one gene randomly selected from each of 15
rank-ordered strata.
Oligonucleotide primer design for quantitative real time 
polymerase chain reaction
The cDNA and genomic sequences of all selected genes
were obtained and the Primer 3 web tool [35] was used to
select pairs of oligonucleotide primers with an optimal
melting temperature of 60°C. Primer pairs were selected
to span an intron/exon junction, except for a few genes
where this was not possible, such as intronless genes.
Quantitative real time polymerase chain reaction
All primer pairs were tested by the polymerase chain reac-
tion [1× reaction buffer, 3.5 µM MgCl2, 0.2 mM dNTP, 0.2
µM of each primer, 5 ng cDNA template (labeled as
above), 0.25 U Hotstart Taq polymerase (Qiagen)] and
agarose gel electrophoresis to verify the presence of a sin-
gle band of the predicted size. Selected pairs were tested in
quantitative real time polymerase chain reactions
(qrPCR) on an ABI Prism® 7900HT sequence detection
system (Applied Biosystems). Each combination of 50,
150 and 300 nM of forward and reverse primer was tested
in duplicate reactions [1× reaction buffer, 3.5 µM MgCl2,
0.2 mM dNTP, varying concentrations of primer, 0.04 µM
ROX (Molecular probes), 1× SYBR-green 1 (from a 10
000× stock, Molecular probes), 1× bovine serum albumin
(New England Biolabs), 5 ng cDNA template, 0.25 U Hot-
start Taq polymerase (Qiagen)] and the optimal reaction
condition was selected. For each gene, we prepared 6 tech-
nical replicate reactions of the following: a calibration
curve from a two-fold dilution series ranging from 20 to
0.078 ng of cDNA (9 dilutions), a control containing no
cDNA, and each of the six experimental samples; 16
groups in total, for a total of 96 qrPCR reactions. The
placement of the 16 groups of qrPCR reactions within the
384-well plates was randomized for every gene such that
the samples would not always be located at the same place
on the plate. All the qrPCR reactions for a given gene were
run in parallel on the same plate. The results from the
three control and the three treatment samples were then
calculated by comparison to the calibration curve. Seven
standard curve data points (for five of the 29 genes) had
large influence on the regression slope (as indicated by
|standardized slope dfBeta| values > 1, [27]). These data
points were deleted, and the data were recalibrated. The
experimental samples were calibrated according to their
respective standard curve equations. Fifty-four of the 1044
calibrated values were found to be outliers (defined as
one-and-a-half (1.5) times the inter-quartile range
beyond the 25th and 75th percentile values). These outliers
were deleted prior to averaging.
Abbreviations
CCC : concordance correlation coefficient.
FC : fold-change.
FDR : false discovery rate.
qrPCR: quantitative real time polymerase chain reaction.
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